RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ocular Therapeutix Stock

Ocular Therapeutix ROCE 2024

Ocular Therapeutix ROCE

-0.9

Ticker

OCUL

ISIN

US67576A1007

WKN

A1180P

In 2024, Ocular Therapeutix's return on capital employed (ROCE) was -0.9, a -59.31% increase from the -2.22 ROCE in the previous year.

Ocular Therapeutix Aktienanalyse

What does Ocular Therapeutix do?

Ocular Therapeutix Inc is a US biotechnology company founded in 2006 by Amarpreet Sawhney and Michael Goldstein. Its focus is on the development and commercialization of ocular therapeutics. Ocular Therapeutix's business model is based on the use of proprietary technologies such as the hydrogel platform (which involves the use of hydrophilic polymers to develop AMC-based therapeutics), the compounds embedded in the polymer matrix, and the bonding technology to develop new drug candidates. The company utilizes these technologies to develop and bring to market products that have the potential to meet clinical needs of patients. Ocular Therapeutix operates in two divisions - Retina and Severe Eye Diseases, and Dry Eye. The Retina and Severe Eye Diseases division focuses on the development of drugs for the treatment of retina diseases such as wet age-related macular degeneration, diabetic retinopathy, and macular edema. In this division, the company has developed DEXTENZA, which is used for the treatment of postoperative pain and inflammation after eye surgeries. DEXTENZA is a single-use implant that continuously releases medication and relieves inflammation. The Dry Eye division of Ocular Therapeutix focuses on the development and commercialization of drugs for the treatment of dry eye, a condition caused by inadequate tear production or quality. In this division, the company has developed ReSure Sealant - a hydrophilic bonding technology used to seal the eye surface during surgeries and injuries while maintaining eye moisture and preventing infections. Currently, the company is also developing DEXTENZA for the treatment of dry eye. The company is actively involved in research and development of new therapy options and has recently expanded its pipeline extensively. Ocular Therapeutix will soon expand to Europe and Asia and plans to market its products in various regions worldwide. Overall, Ocular Therapeutix has made significant progress in recent years by expanding its product range and advancing drug development. With a well-positioned pipeline and a growing business, the company is expected to achieve significant growth in the coming years. Ocular Therapeutix ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Ocular Therapeutix's Return on Capital Employed (ROCE)

Ocular Therapeutix's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Ocular Therapeutix's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Ocular Therapeutix's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Ocular Therapeutix’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Ocular Therapeutix stock

What is the ROCE (Return on Capital Employed) of Ocular Therapeutix this year?

The ROCE of Ocular Therapeutix is -0.9 undefined this year.

How has the ROCE (Return on Capital Employed) of Ocular Therapeutix developed compared to the previous year?

The ROCE of Ocular Therapeutix has increased by -59.31% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Ocular Therapeutix?

A high Return on Capital Employed (ROCE) indicates that Ocular Therapeutix has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Ocular Therapeutix?

A low ROCE (Return on Capital Employed) can indicate that Ocular Therapeutix has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Ocular Therapeutix impact the company?

An increase in the ROCE of Ocular Therapeutix can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Ocular Therapeutix affect the company?

A decrease in ROCE of Ocular Therapeutix can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Ocular Therapeutix?

Some factors that can affect Ocular Therapeutix's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Ocular Therapeutix so important for investors?

The ROCE of Ocular Therapeutix is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Ocular Therapeutix take to improve the ROCE?

To improve the ROCE, Ocular Therapeutix can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Ocular Therapeutix pay?

Over the past 12 months, Ocular Therapeutix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ocular Therapeutix is expected to pay a dividend of 0 USD.

What is the dividend yield of Ocular Therapeutix?

The current dividend yield of Ocular Therapeutix is .

When does Ocular Therapeutix pay dividends?

Ocular Therapeutix pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ocular Therapeutix?

Ocular Therapeutix paid dividends every year for the past 0 years.

What is the dividend of Ocular Therapeutix?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ocular Therapeutix located?

Ocular Therapeutix is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ocular Therapeutix kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ocular Therapeutix from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Ocular Therapeutix pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Ocular Therapeutix in the year 2023?

In the year 2023, Ocular Therapeutix distributed 0 USD as dividends.

In which currency does Ocular Therapeutix pay out the dividend?

The dividends of Ocular Therapeutix are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Ocular Therapeutix stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Ocular Therapeutix

Our stock analysis for Ocular Therapeutix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ocular Therapeutix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.